Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many claims about indication, PDE5 inhibitor mechanism, and common adverse reactions match the provided label text. However, several safety/interaction statements are partially supported or overgeneralized, and some claims about switching, dosing/food timing, and drug-family comparisons are not supported by the supplied label excerpts.
Category Scores
Accurate Statements
Levitra is a brand name for vardenafil.
DOSAGE AND ADMINISTRATION / CONTRAINDICATIONS / CLINICAL PHARMACOLOGY: LEVITRA is vardenafil (implied throughout by “vardenafil” text in the LEVITRA label).
Levitra is an oral medicine used to treat erectile dysfunction (ED) in men.
INDICATIONS AND USAGE: indicated for treatment of erectile dysfunction; DOSAGE AND ADMINISTRATION: taken orally; label is written for men.
Levitra helps improve the ability to get and maintain an erection when sexually stimulated.
DOSAGE AND ADMINISTRATION: “Sexual stimulation is required for a response to treatment.” CLINICAL PHARMACOLOGY: mechanism explains increased blood flow/erection during stimulation.
Levitra (vardenafil) is a PDE5 inhibitor.
CLINICAL PHARMACOLOGY: “selective inhibitor of PDE5” (Mechanism of Action).
Levitra helps relax blood vessels in the penis.
CLINICAL PHARMACOLOGY: nitric oxide/cGMP triggers smooth muscle relaxation and “allowing increased blood flow into the penis, resulting in erection.”
Levitra increases blood flow during sexual stimulation.
CLINICAL PHARMACOLOGY: “allowing increased blood flow into the penis, resulting in erection.”
Levitra is taken by mouth shortly before sex.
DOSAGE AND ADMINISTRATION and Information for Patients: “taken approximately 60 minutes before sexual activity.”
How long it takes Levitra to work can vary by person.
Not explicitly stated in the provided label excerpts; however, “taken approximately 60 minutes before sexual activity” and “sexual stimulation is required” are consistent with variability not described. (No direct quote found in provided excerpts.)
Common side effects linked to PDE5 inhibitors like vardenafil can include headache.
ADVERSE REACTIONS Table 5: Headache 15% (LEVITRA) vs 4% (placebo).
Common side effects linked to PDE5 inhibitors like vardenafil can include flushing.
ADVERSE REACTIONS Table 5: Flushing 11% (LEVITRA) vs 1% (placebo).
Common side effects linked to PDE5 inhibitors like vardenafil can include stuffy nose.
ADVERSE REACTIONS Table 5: Rhinitis 9% (LEVITRA) vs 3% (placebo). (Stuffy nose corresponds to rhinitis; label uses “rhinitis.”)
Common side effects linked to PDE5 inhibitors like vardenafil can include dizziness.
ADVERSE REACTIONS Table 5: Dizziness 2% (LEVITRA) vs 1% (placebo).
Common side effects linked to PDE5 inhibitors like vardenafil can include indigestion.
ADVERSE REACTIONS Table 5: Dyspepsia 4% (LEVITRA) vs 1% (placebo) (indigestion corresponds to dyspepsia).
Patients should stop and seek urgent care for serious symptoms such as fainting.
Information for Patients: nitrates with PDE5 inhibitors could cause dizziness/syncope; and alpha-blockers can lower BP leading to “symptomatic hypotension (e.g., fainting).”
Patients should stop and seek urgent care for serious symptoms such as signs of an allergic reaction.
ADVERSE REACTIONS: lists “anaphylactic reaction (including laryngeal edema)” in <2% events; label advises stopping/seek medical attention for serious events in Information for Patients sections provided for vision/hearing (not allergy explicitly). (Support is partial for allergy seriousness but not for “seek urgent care” wording.)
Levitra is not appropriate for everyone.
WARNINGS/CARDIOVASCULAR effects: physicians should consider cardiovascular status; CONTRAINDICATIONS: nitrates and hypersensitivity. (General phrasing is supported by existence of contraindications/precautions.)
Combining nitrates with PDE5 inhibitors can cause dangerous blood-pressure drops.
CONTRAINDICATIONS: administration with nitrates and nitric oxide donors is contraindicated; Information for Patients: could cause blood pressure to suddenly drop to an unsafe level, resulting in dizziness, syncope, etc.
Patients need clinician guidance if they have certain heart conditions or take interacting medications.
WARNINGS: cardiovascular status; Information for Patients: discuss with patients potential cardiac risk and contact prescribing physician if other medications that may interact are prescribed. DOSAGE AND ADMINISTRATION: dose adjustment with CYP3A4 inhibitors and caution with alpha-blockers.
If Levitra is not effective or causes unacceptable side effects, clinicians may adjust timing/dosing strategy.
DOSAGE AND ADMINISTRATION: dose may be increased/decreased based on efficacy and side effects; Information for Patients: contact provider for dose modification if not satisfied with quality or in case of an unwanted effect.
Some patients need a full medication review for interactions, especially with blood-pressure drugs or nitrate therapy.
Information for Patients: contact prescribing physician if other anti-hypertensive drugs or new medications that may interact are prescribed; CONTRAINDICATIONS: nitrates; DOSAGE AND ADMINISTRATION: alpha-blocker caution and CYP3A4 inhibitors.
Unsupported Statements
Patients typically take Levitra before sexual activity.
Label states it should be taken approximately 60 minutes before sexual activity, but the phrase “typically take” is not directly stated.
How long it takes Levitra to work can vary by person.
Provided label excerpts do not explicitly state variability in time-to-effect by person.
How long it takes Levitra to work depends on whether it is taken with food, especially heavy or fatty meals.
DOSAGE AND ADMINISTRATION excerpt says it can be taken with or without food; no heavy/fatty meal timing dependence is provided.
Levitra helps relax blood vessels in the penis.
Label supports smooth muscle relaxation in corpus cavernosum and increased blood flow, but does not explicitly say “blood vessels” in the penis.
Levitra, Viagra (sildenafil), and Cialis (tadalafil) are all ED medicines in different drug families within the same general class (PDE5 inhibition).
The provided label excerpts discuss only LEVITRA; no label support for comparative statements about Viagra/Cialis drug families or class framing.
Levitra, Viagra, and Cialis differ in onset and duration of action.
No comparative onset/duration information for sildenafil/tadalafil is present in the supplied label text.
Individual tolerability varies among Levitra, Viagra, and Cialis.
No comparative tolerability statements in supplied label excerpts.
Switching among Levitra, Viagra, and Cialis is usually handled by a clinician based on timing needs, side effects, and other medications.
The supplied label excerpt supports dose modification of LEVITRA but does not support switching among these specific other brands/actives.
Pricing and availability of Levitra generics depend on when competing products entered the market.
No label content about pricing, market entry, or generic availability.
Levitra’s patent and exclusivity status determines market access for generics.
No label content about patents/exclusivity/market access.
Patent life and exclusivity for vardenafil (Levitra) can vary by geography.
No label content about geography-specific patent/exclusivity.
Patent life and exclusivity for vardenafil (Levitra) can vary by the specific formulation.
No label content about formulation-specific patent/exclusivity.
If Levitra is not effective or causes unacceptable side effects, clinicians may switch to another PDE5 inhibitor (like sildenafil or tadalafil).
Provided label excerpt supports dose modification and need for clinician contact, but does not explicitly discuss switching to sildenafil/tadalafil.
Contradictions
Important Omissions
Key contraindication detail: LEVITRA is contraindicated with nitrates (regularly or intermittently) and nitric oxide donors, and contraindicated in patients with known hypersensitivity to any tablet component (which are not explicitly stated in the AI response as verbatim contraindications).
Importance:
Moderate
Important interaction warning not explicitly captured: no suitable time interval following LEVITRA dosing has been determined for safe administration of nitrates/nitric oxide donors.
Importance:
Moderate
Alpha-blocker interaction specificity: concomitant use should be initiated only if alpha-blocker patient is stable and LEVITRA should be started at lowest dose (with mention of symptomatic hypotension/fainting); AI only generally mentioned clinician guidance.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
General safety/interaction messaging is present (notably nitrates and symptomatic hypotension examples), but several potentially critical details are not explicitly reflected (exact contraindications with nitrates/nitric oxide donors and lack of established safe interval; more specific alpha-blocker initiation/stability requirements).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claims are unsupported by the provided label excerpts, and some safety/interaction elements are generalized/omitted despite being material (notably nitrates/nitric oxide donors contraindication details and alpha-blocker initiation/stability guidance).
Suggested Improvement
Limit claims to what is explicitly supported by the label excerpts: use the label’s contraindication language for nitrates/nitric oxide donors, avoid asserting food/meal timing dependence, and avoid cross-brand (Viagra/Cialis) comparative and market/patent statements unless supported in the provided label text.